JP2021502415A - 癌の処置のためのアパチニブを用いる併用療法 - Google Patents

癌の処置のためのアパチニブを用いる併用療法 Download PDF

Info

Publication number
JP2021502415A
JP2021502415A JP2020544367A JP2020544367A JP2021502415A JP 2021502415 A JP2021502415 A JP 2021502415A JP 2020544367 A JP2020544367 A JP 2020544367A JP 2020544367 A JP2020544367 A JP 2020544367A JP 2021502415 A JP2021502415 A JP 2021502415A
Authority
JP
Japan
Prior art keywords
administered
riboceranib
amount
cancer
nivolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502415A5 (enExample
Inventor
エヌ． マックギン，アーロ
エヌ． マックギン，アーロ
キム，バムジン
チュル キム，スン
チュル キム，スン
ヘ パク，チョル
ヘ パク，チョル
Original Assignee
エレバー セラピューティクス，インク．
エレバー セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エレバー セラピューティクス，インク．, エレバー セラピューティクス，インク． filed Critical エレバー セラピューティクス，インク．
Publication of JP2021502415A publication Critical patent/JP2021502415A/ja
Publication of JP2021502415A5 publication Critical patent/JP2021502415A5/ja
Priority to JP2024063774A priority Critical patent/JP2024095791A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544367A 2017-11-10 2018-11-09 癌の処置のためのアパチニブを用いる併用療法 Pending JP2021502415A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063774A JP2024095791A (ja) 2017-11-10 2024-04-11 癌の処置のためのアパチニブを用いる併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584547P 2017-11-10 2017-11-10
US62/584,547 2017-11-10
PCT/US2018/060179 WO2019094832A1 (en) 2017-11-10 2018-11-09 A combination therapy with apatinib for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063774A Division JP2024095791A (ja) 2017-11-10 2024-04-11 癌の処置のためのアパチニブを用いる併用療法

Publications (2)

Publication Number Publication Date
JP2021502415A true JP2021502415A (ja) 2021-01-28
JP2021502415A5 JP2021502415A5 (enExample) 2021-12-16

Family

ID=66439039

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544367A Pending JP2021502415A (ja) 2017-11-10 2018-11-09 癌の処置のためのアパチニブを用いる併用療法
JP2024063774A Withdrawn JP2024095791A (ja) 2017-11-10 2024-04-11 癌の処置のためのアパチニブを用いる併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063774A Withdrawn JP2024095791A (ja) 2017-11-10 2024-04-11 癌の処置のためのアパチニブを用いる併用療法

Country Status (6)

Country Link
US (1) US20200282052A1 (enExample)
EP (1) EP3706746A4 (enExample)
JP (2) JP2021502415A (enExample)
KR (1) KR20200107934A (enExample)
CA (1) CA3082095A1 (enExample)
WO (1) WO2019094832A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106176757B (zh) * 2015-05-25 2019-12-10 江苏恒瑞医药股份有限公司 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
WO2021047623A1 (en) * 2019-09-11 2021-03-18 Beigene, Ltd. Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
CN112741905A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 Vegfr抑制剂与抗pd-1抗体联合在制备治疗妊娠滋养细胞肿瘤的药物中的用途
US20230181593A1 (en) * 2020-05-21 2023-06-15 The Regents Of The University Of California Compositions and methods for treating breast cancer
CN111558044B (zh) * 2020-06-01 2022-02-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种包含舒尼替尼的药物组合物及其制剂和应用
WO2024129903A1 (en) * 2022-12-13 2024-06-20 Elevar Therapeutics, Inc. Pharmaceutical formulations of a tyrosine kinase inhibitor
WO2024130026A1 (en) * 2022-12-16 2024-06-20 Elevar Therapeutics, Inc. Methods and compositions for treatment of subjects with hepatic impairments
WO2025024564A1 (en) * 2023-07-24 2025-01-30 The Board Of Regents Of The University Of Texas System Small molecules that prevent statin-induced accumulation of hmg coa reductase
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
BR112017004826A2 (pt) * 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
CA2978226C (en) * 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FRESHWATER, T. ET AL.: "Evaluation of dosing strategy for pembrolizumab for oncology indications", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5, JPN6023008900, 16 May 2017 (2017-05-16), pages 43, ISSN: 0005216489 *
HAZARIKA, M. ET AL.: "U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following", CLINICAL CANCER RESEARCH, vol. 23, no. 14, JPN6023050853, 15 July 2017 (2017-07-15), pages 3484 - 3488, ISSN: 0005216488 *
LAI, J. ET AL.: "Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymph", BMC CANCER, vol. 17, no. 1, JPN6022044085, 28 July 2017 (2017-07-28), pages 507, XP055590207, ISSN: 0005006495, DOI: 10.1186/s12885-017-3501-4 *
LI, J. ET AL.: "Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibit", BMC CANCER, vol. 10, JPN6023008902, 2010, pages 529, XP021075351, ISSN: 0005216487, DOI: 10.1186/1471-2407-10-529 *
MA, F. C. ET AL.: "Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient t", ONCOTARGETS AND THERAPY, vol. 10, JPN6022044082, 1 November 2017 (2017-11-01), pages 5237 - 5242, ISSN: 0005006494 *
SUNSHINE, J., TAUBE, J. M.: "PD-1/PD-L1 inhibitors", CURRENT OPINION IN PHARMACOLOGY, vol. 23, JPN6022044087, 2015, pages 32 - 38, XP055304528, ISSN: 0005006497, DOI: 10.1016/j.coph.2015.05.011 *
YASUDA, S. ET AL.: "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 172, no. 3, JPN6022044086, 2013, pages 500 - 506, XP071081713, ISSN: 0005006496, DOI: 10.1111/cei.12069 *
ZHAO, X. ET AL.: "Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regi", ANNALS OF ONCOLOGY, vol. 28, no. 8, JPN6023008901, 1 August 2017 (2017-08-01), pages 2002 - 2008, XP002789767, ISSN: 0005216490, DOI: 10.1093/annonc/mdx235 *

Also Published As

Publication number Publication date
EP3706746A4 (en) 2021-12-15
KR20200107934A (ko) 2020-09-16
JP2024095791A (ja) 2024-07-10
CA3082095A1 (en) 2019-05-16
US20200282052A1 (en) 2020-09-10
EP3706746A1 (en) 2020-09-16
WO2019094832A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
JP6974669B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
JP2021502415A (ja) 癌の処置のためのアパチニブを用いる併用療法
CN105338980A (zh) 药物组合
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
TWI814504B (zh) 治療癌症之方法
US20230149377A1 (en) Pharmaceutical methods
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CN116265030A (zh) 包含酪氨酸激酶抑制剂德立替尼的药物组合
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物
WO2023078408A1 (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221019

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212